HOLLISTON, Mass., Feb. 22, 2018 -- Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will announce results for its fourth quarter 2017 after market trading hours on Thursday, March 1, 2018. A conference call to discuss the company's fourth quarter 2017 financial results and its operations is scheduled for that same date at 4:30 PM ET. On that call, management may respond to questions from the audience and provide information on any of a number of topics related to the business, including operations, plans and outlook.
Participating in the call will be Jeffrey A. Duchemin, President and Chief Executive Officer; and Robert Gagnon, Chief Financial Officer of Harvard Bioscience. Investors can access the live conference call by dialing the following phone numbers: toll-free 1-888-771-4371, or international: 1-847-585-4405, and referencing the conference ID# 46530979.
The conference will be simultaneously webcast and can be accessed through the Harvard Bioscience website. To listen to the webcast, log on to the webcast at:
http://investor.harvardbioscience.com/
and click on the Earnings Call icon. Financial information presented on the call, including the earnings release, will also be available on the investor relations section of the website.
If you are unable to listen to the live conference call, the webcast will be available on the Company's website through March 8, 2018.
To add this meeting to your calendar visit: http://investor.harvardbioscience.com/ and click “remind me”.
About Harvard Bioscience
Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of solutions to advance life science. Our products are sold to thousands of researchers in over 100 countries through our global sales organization, websites, catalogs, and through distributors including Thermo Fisher Scientific Inc., VWR, and other specialized distributors. We have sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden, Spain, France, Canada and China. For more information, please visit our website at www.harvardbioscience.com.
CONTACTS: Corey Manchester Director, Finance and Investor Relations Tel: 508 893 8999


Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+
Shein Scales Back Vietnam Operations as US Trade Rules Shift
DeepSeek to Raise AI API Prices as Demand for New Models Surges
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 



